Samsung Biologics and Pfizer collaborate for long-term manufacturing of biosimilars portfolio
Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
Pfizer is likely to show GSK significant competition
The application is in line with Innocan's strategy to expand the scope of its combined magnesium and cannabis topical solution
UTD2 is the world's first oral epothilone microtubule inhibitor
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
The new API plant is set up to meet all domestic and international regulatory standards and will manufacture niche molecules that have a global requirement
New facility will strengthen the security of supply for global pharmaceutical and biotech customers and will support the continued development and production of lifesaving clinical and commercial-scale therapeutics for patients worldwide.
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
The company expects this approval in Baddi to pave the way for GMP certifications from European Medicines Agency and other PIC/S member nations
Subscribe To Our Newsletter & Stay Updated